Balbi, Gustavo GM;
Ahmadzadeh, Yasaman;
Tektonidou, Maria G;
Pengo, Vittorio;
Sciascia, Savino;
Ugarte, Amaia;
Belmont, H Michael;
... Oliveira de Andrade, Danieli Castro; + view all
(2024)
Damage measured by Damage Index for Antiphospholipid Syndrome (DIAPS) in antiphospholipid antibody-positive patients included in the APS ACTION registry.
Rheumatology
, 63
(3)
pp. 772-779.
10.1093/rheumatology/kead292.
Preview |
Text
Efthymiou_Damage measured by Damage Index for Antiphospholipid Syndrome (DIAPS) in antiphospholipid antibody-positive patients included in the APS ACTION registry_AAM.pdf Download (542kB) | Preview |
Abstract
OBJECTIVES: Our primary objective was to quantify damage burden measured by Damage Index for Antiphospholipid Syndrome (DIAPS) in antiphospholipid antibody (aPL)-positive patients with or without a history of thrombosis in an international cohort. Secondly, we aimed to identify clinical and laboratory characteristics associated with damage in aPL-positive patients. METHODS: In this cross-sectional study, we analyzed the baseline damage in aPL-positive patients with or without APS classification. We excluded patients with other autoimmune diseases. We analyzed the demographic, clinical, and laboratory characteristics based on two subgroups: (1) thrombotic APS patients with high versus low damage; and (2) non-thrombotic aPL-positive patients with versus without damage. RESULTS: Of the 826 aPL-positive patients included in the registry as of April 2020, 576 with no other systemic autoimmune diseases were included in the analysis (412 thrombotic and 164 non-thrombotic). In the thrombotic group, hyperlipidemia (OR 1.82, 95%CI 1.05-3.15, adjusted p= 0.032), obesity (OR 2.14, 95%CI 1.23-3.71, adjusted p= 0.007), aβ2GPI high titers (OR 2.33, 95%CI 1.36-4.02, adjusted p= 0.002), and corticosteroids use (ever) (OR 3.73, 95%IC 1.80-7.75, adjusted p< 0.001) were independently associated with high damage at baseline. In the non-thrombotic group, hypertension (OR 4.55, 95%CI 1.82-11.35, adjusted p= 0.001) and hyperlipidemia (OR 4.32, 95%CI 1.37-13.65, adjusted p= 0.013) were independent predictors of damage at baseline; conversely, single aPL positivity was inversely correlated with damage (OR 0.24; 95%CI 0.075-0,77, adjusted p= 0.016). CONCLUSIONS: DIAPS indicates substantial damage in aPL-positive patients in APS ACTION cohort. Selected traditional cardiovascular risk factors, steroids use and specific aPL profiles may help to identify patients more prone to present with a higher damage burden.
| Type: | Article |
|---|---|
| Title: | Damage measured by Damage Index for Antiphospholipid Syndrome (DIAPS) in antiphospholipid antibody-positive patients included in the APS ACTION registry |
| Location: | England |
| Open access status: | An open access version is available from UCL Discovery |
| DOI: | 10.1093/rheumatology/kead292 |
| Publisher version: | https://doi.org/10.1093/rheumatology/kead292 |
| Language: | English |
| Additional information: | This version is the author accepted manuscript. For information on re-use, please refer to the publisher's terms and conditions. |
| Keywords: | antiphospholipid syndrome, antiphospholipid antibodies, lupus anticoagulant, anticardiolipin, anti-beta-2 glycoprotein I antibodies, damage, cardiovascular disease, risk factors |
| UCL classification: | UCL UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Medical Sciences UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Medical Sciences > Cancer Institute UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Medical Sciences > Cancer Institute > Research Department of Haematology |
| URI: | https://discovery.ucl.ac.uk/id/eprint/10177844 |
Archive Staff Only
 |
View Item |
